Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics

Bristol-Myers Squibb Company BMY announced today that the Hart-Scott-Rodino (HSR) waiting period for its tender offer for ZymoGenetics, Inc. ZGEN has expired. Bristol-Myers Squibb initiated on September 10, 2010, through its wholly-owned subsidiary Zeus Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics for $9.75 per share. Analyze Any Stock FREE! Click Here.